A functional genomics approach to the mode of action of apratoxin A
- 12 February 2006
- journal article
- research article
- Published by Springer Nature in Nature Chemical Biology
- Vol. 2 (3) , 158-167
- https://doi.org/10.1038/nchembio769
Abstract
The cyanobacterial metabolite apratoxin A (1) demonstrates potent cytotoxicity against tumor cell lines by a hitherto unknown mechanism. We have used functional genomics to elucidate the molecular basis for this activity. Gene expression profiling and DNA content analysis showed that apratoxin A induces G1-phase cell cycle arrest and apoptosis. Cell-based functional assays with a genome-wide collection of expression cDNAs showed that ectopic induction of fibroblast growth factor receptor (FGFR) signaling attenuates the apoptotic activity of apratoxin A. This natural product inhibited phosphorylation and activation of STAT3, a downstream effector of FGFR signaling. It also caused defects in FGF-dependent processes during zebrafish development, with concomitant reductions in expression levels of the FGF target gene mkp3. We conclude that apratoxin A mediates its antiproliferative activity through the induction of G1 cell cycle arrest and an apoptotic cascade, which is at least partially initiated through antagonism of FGF signaling via STAT3.Keywords
This publication has 44 references indexed in Scilit:
- Cryptophycins-309, 249 and other cryptophycin analogs: Preclinical efficacy studies with mouse and human tumorsInvestigational New Drugs, 2005
- Total synthesis of the marine cyanobacterial cyclodepsipeptide apratoxin AProceedings of the National Academy of Sciences, 2004
- GOstat: find statistically overrepresented Gene Ontologies within a group of genesBioinformatics, 2004
- Natural Products as Sources of New Drugs over the Period 1981−2002Journal of Natural Products, 2003
- Phase 2 study of cryptophycin 52 ( LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancerLung Cancer, 2003
- New apratoxins of marine cyanobacterial origin from guam and palauBioorganic & Medicinal Chemistry, 2002
- Anticancer therapy with novel tubulin-interacting drugsDrug Resistance Updates, 2001
- Isolation of Dolastatin 10 from the Marine Cyanobacterium Symploca Species VP642 and Total Stereochemistry and Biological Evaluation of Its Analogue Symplostatin 1Journal of Natural Products, 2001
- Total Structure Determination of Apratoxin A, a Potent Novel Cytotoxin from the Marine Cyanobacterium Lyngbya majusculaJournal of the American Chemical Society, 2001
- Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycleOncogene, 1998